114 related articles for article (PubMed ID: 20388035)
1. Immunosuppressive treatments reduce long-term immunity to smallpox among patients with breast cancer.
Wiser I; Orr N; Kaufman B; Segev S; Smetana Z; Bialik A; Epstein N; Mendelson E; Catane R; Cohen D
J Infect Dis; 2010 May; 201(10):1527-34. PubMed ID: 20388035
[TBL] [Abstract][Full Text] [Related]
2. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.
Kim SH; Yeo SG; Park KH; Bang JW; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
Clin Microbiol Infect; 2007 Jan; 13(1):91-3. PubMed ID: 17184294
[TBL] [Abstract][Full Text] [Related]
3. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations.
Hatakeyama S; Moriya K; Saijo M; Morisawa Y; Kurane I; Koike K; Kimura S; Morikawa S
Clin Diagn Lab Immunol; 2005 Apr; 12(4):520-4. PubMed ID: 15817760
[TBL] [Abstract][Full Text] [Related]
4. Dose-related effects of smallpox vaccine.
Frey SE; Newman FK; Cruz J; Shelton WB; Tennant JM; Polach T; Rothman AL; Kennedy JS; Wolff M; Belshe RB; Ennis FA
N Engl J Med; 2002 Apr; 346(17):1275-80. PubMed ID: 11923489
[TBL] [Abstract][Full Text] [Related]
5. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
[TBL] [Abstract][Full Text] [Related]
6. Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.
Pittman PR; Garman PM; Kim SH; Schmader TJ; Nieding WJ; Pike JG; Knight R; Johnston SC; Huggins JW; Kortepeter MG; Korman L; Ranadive M; Quinn X; Meyers MS
Vaccine; 2015 Jun; 33(26):2990-6. PubMed ID: 25930115
[TBL] [Abstract][Full Text] [Related]
7. Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination.
Trojan A; Rajeswaran R; Montemurro M; Mütsch M; Steffen R
J Clin Virol; 2007 Sep; 40(1):80-3. PubMed ID: 17644471
[TBL] [Abstract][Full Text] [Related]
8. Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.
Kennedy JS; Frey SE; Yan L; Rothman AL; Cruz J; Newman FK; Orphin L; Belshe RB; Ennis FA
J Infect Dis; 2004 Oct; 190(7):1286-94. PubMed ID: 15346340
[TBL] [Abstract][Full Text] [Related]
9. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults.
Treanor J; Wu H; Liang H; Topham DJ
Vaccine; 2006 Nov; 24(47-48):6913-23. PubMed ID: 17014939
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain.
Hsieh SM; Chen SY; Sheu GC; Hung MN; Chou WH; Chang SC; Hsu KH
Vaccine; 2006 Jan; 24(4):510-5. PubMed ID: 16139395
[TBL] [Abstract][Full Text] [Related]
12. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cells after smallpox vaccination.
Ennis FA; Cruz J; Demkowicz WE; Rothman AL; McClain DJ
J Infect Dis; 2002 Jun; 185(11):1657-9. PubMed ID: 12023773
[TBL] [Abstract][Full Text] [Related]
13. Bioterrorism. Smallpox vaccinations: how much protection remains?
Cohen J
Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
[No Abstract] [Full Text] [Related]
14. Prediction of residual immunity to smallpox, by means of an intradermal skin test with inactivated vaccinia virus.
Kim SH; Bang JW; Park KH; Park WB; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
J Infect Dis; 2006 Aug; 194(3):377-84. PubMed ID: 16826487
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of human immunological responses to vaccinia virus.
Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
[TBL] [Abstract][Full Text] [Related]
16. Serological Immunity to Smallpox in New South Wales, Australia.
Costantino V; Trent MJ; Sullivan JS; Kunasekaran MP; Gray R; MacIntyre R
Viruses; 2020 May; 12(5):. PubMed ID: 32443405
[TBL] [Abstract][Full Text] [Related]
17. Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.
Kan VL; Manischewitz J; King LR; Golding H
AIDS; 2007 Feb; 21(4):521-4. PubMed ID: 17301573
[TBL] [Abstract][Full Text] [Related]
18. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
20. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
